Healthcare
Vantis Vascular
Recorded December 11, 2025
Vantis Vascular is developing breakthrough tools to deliver game-changing outcomes in advanced vascular intervention
Vantis Vascular is developing breakthrough tools to deliver game-changing outcomes in advanced vascular intervention
Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials with the potential to become standard of care in markets worth a total of $26B.
Duo Oncology is a next-generation biotech company creating a nanomedicine platform that replaces chemotherapy for hard-to-treat cancers
Duo Oncology is a next-generation biotech company creating a nanomedicine platform that replaces chemotherapy for hard-to-treat cancers
Xgene is using its proprietary conjugate platform technology to provide highly effective non-opioid relief for acute and chronic pain
Xgene is using its proprietary conjugate platform technology to provide highly effective non-opioid relief for acute and chronic pain
Auctus Vertical Body Tethering has received a Breakthrough Device Designation and Humanitarian Device Exemption Pathway from the FDA
BrainScope has a pipeline that spans stroke, Alzheimer’s, concussion, and beyond, and is uniquely positioned in a $21B+ global market
Breakthru Medicine is developing precision cancer therapies targeting an $18B+ solid cancer market with massive unmet need
Auctus Vertical Body Tethering has received a Breakthrough Device Designation and Humanitarian Device Exemption Pathway from the FDA
General Oncology, Inc., is advancing late-stage oncology and ophthalmology programs with human proof-of-concept data and a defined path to liquidity.
BrainScope has a pipeline that spans stroke, Alzheimer’s, concussion, and beyond, and is uniquely positioned in a $21B+ global market